Medline (NASDAQ:MDLN) Upgraded by Leerink Partnrs to “Strong-Buy” Rating

Leerink Partnrs upgraded shares of Medline (NASDAQ:MDLN) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on MDLN. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medline in a research note on Monday. They set a “hold” rating and a $40.00 price objective for the company. Barclays began coverage on shares of Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price target for the company. Jefferies Financial Group assumed coverage on Medline in a research report on Monday. They issued a “buy” rating and a $50.00 price objective on the stock. BMO Capital Markets assumed coverage on Medline in a research note on Monday. They set an “outperform” rating and a $45.00 price objective on the stock. Finally, Citigroup assumed coverage on Medline in a research note on Monday. They issued a “buy” rating and a $48.00 target price for the company. Eight equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Medline has an average rating of “Buy” and an average target price of $46.70.

Medline Stock Performance

NASDAQ MDLN opened at $42.72 on Monday. Medline has a 1-year low of $34.89 and a 1-year high of $45.50.

Insider Activity at Medline

In other Medline news, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the purchase, the director owned 2,586,206 shares in the company, valued at $74,999,974. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. The trade was a 55.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.